ASML Overvalued: New DCF Shows 39% Downside; DeepValue WAIT Stands

What happened

ASML stock continued to climb after the July 2026 DeepValue report, reaching $1,812 by October 1, 2026, up from $1,747.6 at the time of that report. A new GuruFocus DCF analysis published that day pegs ASML's intrinsic value at $1,105, far below the market price, suggesting the shares are substantially overvalued. The DeepValue report had already rated ASML a WAIT with an attractive entry at $1,550, citing no margin of safety at 59.4x P/E and relying on flawless execution and capacity expansion to justify the price. The company's operational strength—dominance in EUV, booked 2027 capacity, and raised 2026 guidance—remains intact, but that strength is now priced at an even higher premium. The combined picture is one of a high-quality business whose share price has run ahead of conservative valuation math, leaving investors exposed to execution and geopolitical risks with limited upside.

Implication

The new DCF valuation reinforces the DeepValue WAIT rating and suggests downside risk is more severe than previously estimated. With a market price of $1,812 against a DCF intrinsic value of $1,105, the implied overvaluation is nearly 40%, even before considering execution risks in capacity expansion and China exposure. The DeepValue framework's attractive entry of $1,550 is above the DCF value, indicating that even that level may not offer a sufficient margin of safety. Holders should consider trimming if the stock approaches the $1,900 trim threshold, while potential buyers should remain patient. Key triggers for re-evaluation include ASML reaffirming 2027 capacity plans, quarterly sales exceeding €12.0B, or a material de-rating that brings the price closer to $1,100–1,550.

Thesis delta

The new DCF analysis shifts the valuation reference point lower, from the DeepValue base case of $1,800 to $1,105, deepening the overvaluation concern. This suggests the previous WAIT rating may understate downside risk, as even the report's bear case implied $1,450. The thesis now more strongly favors avoiding new positions and tightening risk controls, pending either a significant price correction or tangible evidence that 2027–2028 capacity conversion will exceed expectations.